This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
QGEN or EXAS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
QGEN vs. EXAS: Which Stock Is the Better Value Option?
What Makes Exact Sciences (EXAS) a New Buy Stock
by Zacks Equity Research
Exact Sciences (EXAS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
What's Fueling Tempus AI's Explosive Sales Growth?
by Sridatri Sarkar
TEM's Q1 revenues jump 75.4%, powered by soaring genomics sales, strategic deals and new test launches.
QGEN vs. EXAS: Which Stock Is the Better Value Option?
by Zacks Equity Research
QGEN vs. EXAS: Which Stock Is the Better Value Option?
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
by Moumi Mondal
TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Hologic Climbs 13% in a Month: How Should You Play the Stock?
by Moumi Mondal
HOLX up 13% over the last month, supported by a rejected $16.7 billion buyout offer and new BCI data. What's the investment outlook?
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
by Zacks Equity Research
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
by Moumi Mondal
HOLX displays cautious fiscal 2025 guidance in a challenging geopolitical and macroeconomic environment. What does it mean for the stock?
EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised
by Zacks Equity Research
Exact Sciences ends the first quarter of 2025 on a solid note.
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 43.24% and 2.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
by Urmimala Biswas
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
Should You Retain Exact Sciences Stock in Your Portfolio Now?
by Zacks Equity Research
EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry.
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Top Cancer Biotechs to Keep An Eye On in 2025
by Kinjel Shah
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock?
by Moumi Mondal
HOLX's latest regulatory successes draw investors' attention. However, macroeconomic challenges restrict its full growth potential.
EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y
by Zacks Equity Research
Exact Sciences' fourth-quarter 2024 performance benefits from the robust momentum in Cologuard adoption.